Trinity Partners worked with Sage Therapeutics to explore the burden of illness for super-refractory status epilepticus patients.

Executives from Trinity Partners and Sage Therapeutics conducted a study to provide an estimate of the annual number of super-refractory status epilepticus (SRSE) cases in the US and to evaluate utilization of hospital resources by these patients, using hospital chargemaser data. The study suggests that SRSE is associated with high mortality and morbidity, and significant use of healthcare resources. Read the full report here: http://www.tandfonline.com/doi/full/10.1080/13696998.2016.1223680?scroll=top&needAccess=true

Trinity’s Herman Sanchez Reflects on the Specialty Drug Market in PharmaVOICE

Partner Herman Sanchez commented on the changing specialty sales and marketing landscape in the October issue of PharmaVOICE. In the story, Herman remarked that companies now routinely involve health economic functions early in the decision-making process and in the development of the core value proposition. Said Herman, “Developing a value story for the product is now absolutely essential to the success of the product.”

The article is available online, here. To learn more about Herman Sanchez and our other partners, click here.

Trinity’s Leslie Sandberg Orne Quoted in PharmaVOICE

In the September issue of PharmaVOICE, Senior Partner Leslie Sandberg Orne comments on the challenges behind marketing CNS therapies. In the story, Leslie addresses the top factors driving CNS prescribing habits, as well as the reimbursement process for CNS therapies and how the marketplace may evolve in the next 5-10 years.

 

The article is available online, here. To learn more about Leslie Sandberg Orne and our other partners, click here.

Partner Ryan Million, PhD Quoted in Medical Marketing & Media

Trinity Partners’ Ryan Million was quoted in the latest issue of Medical Marketing & Media. Dr. Million’s comments were featured in an article titled “Drugmakers move to counteract expiring patents with new respiratory drugs”. In the article, Dr. Million discusses trends in the development of treatments for orphan and specialty respiratory diseases. To read the full article, please click here.

To learn more about Dr. Million and our full leadership team, click here.